Artemisinin

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: immunity inflammation detox

Research Overview

Across the abstracts, artemisinin and its derivatives are most extensively studied in malaria, where they remain the cornerstone of first-line therapy, and where research emphasis has shifted from discovery and deployment to sustaining efficacy in the face of evolving drug resistance. Modeling and clinical-trial evidence highlighted here supports the development of triple artemisinin-based combination therapies (TACTs), which pair an artemisinin derivative with two partner drugs; these regimens appear efficacious and well tolerated in trials and are predicted by independent individual-based models to delay the emergence and spread of resistance and reduce long-term treatment failure relative to continued use of standard ACTs in settings with emerging multidrug resistance. In parallel, a substantial body of non-malarial research exists, spanning anti-parasitic (non-malaria), anti-inflammatory/immune-mediated conditions, oncology, antiviral indications, dermatology, and mechanistic studies (e.g., ferroptosis-related neuroprotection in cellular models), with a clinical literature that is geographically concentrated in Asia and Africa for anti-parasitic/anti-inflammatory work and more represented in Europe/US for oncology.

The strongest evidence base in these abstracts supports artemisinin’s antimalarial role and the strategic value of combination therapy to preserve effectiveness, with TACTs emerging as a leading candidate approach where resistance is rising. For non-malarial indications, the evidence is more heterogeneous: reviews and clinical-study mappings suggest generally favorable tolerability across diverse trials and signals of efficacy in some anti-parasitic, anti-inflammatory, dermatologic, and anti-tumor contexts, but much of the oncology and neurodegeneration rationale remains driven by preclinical or mechanistic findings (e.g., iron-associated radical formation in cancer cells; protection against ferroptosis in neuronal cell models) and comparatively limited human efficacy data. Network pharmacology is presented as a complementary framework for understanding multi-target and synergistic effects—particularly relevant to traditional medicine-derived therapies—though it functions primarily as a hypothesis-generating approach rather than definitive clinical validation.

Key research gaps include: (i) expanded, well-powered phase II/III randomized trials for non-malarial indications—especially antiviral applications, which are described as limited and largely early-phase; (ii) clearer resolution of efficacy for artemisinin-based combinations in non-malarial parasitic diseases, where results are noted as controversial; (iii) stronger translational bridges from mechanistic findings (e.g., ferroptosis modulation, immunoregulation, anti-angiogenesis) to clinically meaningful endpoints in neurodegenerative disease, autoimmune disorders, and cancer; and (iv) continued surveillance and policy-relevant implementation research for resistance management in malaria, including real-world effectiveness, optimal deployment strategies, and long-term evolutionary impacts of early TACT adoption.

1. What conditions has Artemisinin been studied for?

  • Malaria (Plasmodium falciparum): Artemisinin derivatives are described as the “cornerstone” of current malaria treatment, typically used as artemisinin-based combination therapies (ACTs), with resistance being a major concern.

  • Drug-resistant malaria / resistance prevention strategies: Studied in the context of artemisinin resistance and strategies to delay it, including triple artemisinin-based combination therapies (TACTs).

  • Neurodegenerative disease (Alzheimer’s disease-related mechanisms): Studied for effects on neuronal ferroptosis (lipid peroxidation-driven cell death) relevant to Alzheimer’s disease pathology (cell model evidence).

  • Autoimmune diseases: A review abstract summarizes “accumulating evidence” for immunoregulatory properties and potential across major autoimmune diseases (examples given include rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease).

  • Non-malaria parasitic infections: A clinical research review identified multiple clinical studies in anti-parasitic indications beyond malaria; however, it notes controversy for ACTs in non-malaria parasitic diseases.

  • Cancer (multiple types): Multiple abstracts describe in vitro/in vivo anticancer activity and repurposing interest; clinical experience in humans is described as “scarce” in one abstract.

  • Inflammatory conditions: Clinical research review includes anti-inflammatory studies; another abstract discusses broader repurposing for inflammation/immunoregulation-related diseases.

  • Viral infections (including COVID-19 mentioned as a repurposing target): A clinical research review found antiviral research limited and largely early-phase (phase I). Another abstract mentions COVID-19 as a repurposing topic.

  • Dermatologic/skin diseases: Included among clinical research areas in the clinical review (dermatological treatments).

2. Does it work in treating those conditions? Summarize the evidence.

  • Malaria: Yes—strong established efficacy (but threatened by resistance).

    • Across abstracts, artemisinin derivatives are repeatedly characterized as frontline, most effective antimalarial drugs with high potency and low toxicity, and as the cornerstone of current malaria treatment.

    • However, multiple abstracts emphasize that artemisinin resistance and partner-drug resistance are increasing, threatening malaria control and elimination.

  • Drug-resistant malaria / delaying resistance: Modeling and clinical trial context suggest benefit for TACTs.

    • One abstract reports that TACTs (artemisinin derivative + two partner drugs) were efficacious and well tolerated in clinical trials, including in multidrug-resistant areas.

    • Using two independent individual-based models, introduction of specific TACT regimens was projected to delay emergence/spread of artemisinin resistance and reduce long-term treatment failure compared with continued ACT use; authors conclude immediate introduction should be considered where resistance is emerging.

    • Limitation: the resistance-delaying conclusion is based on modeling (even though efficacy/tolerability is supported by clinical trials in the abstract).

  • Alzheimer’s-related mechanisms (ferroptosis): Promising preclinical evidence, not clinical proof.

    • An abstract states “recent studies” show artemisinin is effective to counteract AD pathology, and reports that in hippocampal HT22 cells, artemisinin pretreatment dose-dependently protected against erastin-induced cell death (a ferroptosis model).

    • Limitation: evidence presented is cell-culture (HT22) and mechanism-focused; no human clinical outcomes are provided in the abstracts.

  • Autoimmune diseases: Suggestive evidence (review-level), clinical effectiveness not established in these abstracts.

    • A review abstract describes “accumulating evidence” and “promising therapeutic potential” of artemisinins in autoimmune diseases via immunoregulatory properties.

    • Limitation: the abstract is a review summary and does not provide specific trial results or effect sizes here.

  • Cancer: Strong laboratory/animal rationale; human evidence limited in these abstracts.

    • Multiple abstracts describe anticancer activity in vitro and in vivo, including mechanisms such as apoptosis, cell-cycle arrest, oxidative stress, inhibition of angiogenesis/migration, and modulation of pathways (e.g., NF-κB, HIF-1α, survivin, NOXA, BMI-1) and autophagy-related processes (autophagy/mitophagy/ferritinophagy).

    • One abstract explicitly states that experience in human cancer is scarce.

    • Some abstracts claim large “case study” experience and minimal cytotoxicity to normal cells, but these are not presented as controlled clinical trials in the provided text; overall, the abstracts support biological plausibility and preclinical promise more than proven clinical efficacy.

  • Other parasitic diseases (non-malaria): Mixed/controversial.

    • A clinical research review found multiple studies and therapeutic effects reported in anti-parasitic indications, but specifically notes that the efficacy of ACTs for parasitic diseases (non-malaria) is still controversial.

  • Antiviral uses: Evidence limited and early-stage.

    • The clinical research review reports antiviral research was limited and mainly in phase I trials (37.50% of antiviral studies), and calls for more phase II/III trials.

  • Anti-inflammatory and dermatologic uses: Some clinical signals, but details limited in abstracts.

    • The clinical research review reports that many studies “discovered therapeutic effects” in anti-inflammatory and dermatological treatments, but the abstract does not provide specific endpoints or comparative results.

3. What health benefits does it have?

  • Proven major benefit: effective treatment of malaria.

    • Artemisinin derivatives are described as highly potent, low-toxicity, frontline antimalarials that have enabled treatment of otherwise drug-resistant parasites and contributed to malaria control/eradication efforts.

  • Potential public-health benefit: slowing resistance via optimized combinations.

    • TACTs are described as efficacious and well tolerated in trials and, in modeling, could delay resistance and extend the useful therapeutic life of antimalarial drugs.

  • Potential neuroprotective benefit (preclinical): protection against ferroptosis-related neuronal injury.

    • In a neuronal cell model, artemisinin protected against erastin-induced ferroptotic cell death, a mechanism implicated in Alzheimer’s disease.

  • Potential immunoregulatory benefit (research-stage): autoimmune disease modulation.

    • Reviews describe immunoregulatory properties of artemisinin derivatives and potential viability across autoimmune diseases, though clinical benefit is not established in the provided abstracts.

  • Potential anticancer benefit (mostly preclinical): multi-pathway anticancer activity and possible synergy with other drugs.

    • Abstracts describe selective anticancer effects across multiple cancer types in vitro/in vivo, involving oxidative stress/free radical generation, apoptosis, cell-cycle arrest, inhibition of angiogenesis/migration, and modulation of autophagy-related pathways; synergy with other anticancer drugs is also described (with the caveat that human evidence is limited in these abstracts).

4. Does it have any downsides or side effects?

  • Resistance is a major downside at the population level (malaria).

    • Multiple abstracts emphasize that increasing artemisinin and partner-drug resistance threatens malaria control and elimination, and reduced sensitivity to artemisinin monotherapy is noted.

  • Adverse events in non-malaria clinical studies: generally reported as low in the reviewed literature, but reporting is limited.

    • The clinical research review states that among 77 included studies (non-malaria indications), 58 mentioned adverse reactions; only one study showed a Grade 3 adverse event, while others did not show related adverse reactions or require discontinuation.

    • Limitation: this summary depends on what trials reported; the abstract does not specify the types of adverse reactions, durations, doses, or comparative rates versus placebo/standard care.

  • Potential mechanistic downsides are not well characterized in these abstracts.

    • Several abstracts emphasize reactive radical generation/oxidative stress as part of anticancer mechanisms; however, the provided abstracts do not quantify clinical toxicity risks from these mechanisms outside malaria use.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report specific pharmacogenomic findings (e.g., genetic variants in drug-metabolizing enzymes or transporters that alter artemisinin efficacy/toxicity in humans).

  • What is discussed instead: parasite evolution and resistance (e.g., “artemisinin resistance” and partner-drug resistance) and modeling of how combination strategies may delay resistance. This is pathogen genetics/evolution, not human pharmacogenomics.

  • Evidence gap: Based on these abstracts alone, no conclusions can be made about whether artemisinin is beneficial or harmful in people with particular human genetic variants.

References

  1. How Can Synergism of Traditional Medicines Benefit from Network Pharmacology?
    Haidan Yuan, Qianqian Ma, Heying Cui, Guancheng Liu, Xiaoyan Zhao (2017)
  2. Artemisinin-resistant malaria.
    N J White, K Chotivanich (2024) - Clinical microbiology reviews
  3. Preventing antimalarial drug resistance with triple artemisinin-based combination therapies.
    Tran Dang Nguyen, Bo Gao, Chanaki Amaratunga, Mehul Dhorda, Thu Nguyen-Anh Tran, Nicholas J White, Arjen M Dondorp, Maciej F Boni, Ricardo Aguas (2023) - Nature communications
  4. Artemisinin inhibits neuronal ferroptosis in Alzheimer's disease models by targeting KEAP1.
    Peng-Xi Deng, Marta Silva, Na Yang, Qing Wang, Xin Meng, Ke-Qiang Ye, Hong-Chang Gao, Wen-Hua Zheng (2025) - Acta pharmacologica Sinica
  5. Artemisinins: Promising drug candidates for the treatment of autoimmune diseases.
    Xu Gao, Xian Lin, Qingwen Wang, Jian Chen (2024) - Medicinal research reviews
  6. New clinical application prospects of artemisinin and its derivatives: a scoping review.
    Yangmu Huang, Yang Yang, Guangqi Liu, Ming Xu (2023) - Infectious diseases of poverty
  7. Artemisinin and its derivatives: a promising cancer therapy.
    Bushra Hafeez Kiani, Waqas Khan Kayani, Asma Umer Khayam, Erum Dilshad, Hammad Ismail, Bushra Mirza (2020) - Molecular biology reports
  8. Discovery and repurposing of artemisinin.
    Qiaoli Shi, Fei Xia, Qixin Wang, Fulong Liao, Qiuyan Guo, Chengchao Xu, Jigang Wang (2022) - Frontiers of medicine
  9. Anticancer Effect of AntiMalarial Artemisinin Compounds.
    A K Das (2015) - Annals of medical and health sciences research
  10. Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?
    Zhaowu Ma, Clariis Yi-Ning Woon, Chen-Guang Liu, Jun-Ting Cheng, Mingliang You, Gautam Sethi, Andrea Li-Ann Wong, Paul Chi-Lui Ho, Daping Zhang, Peishi Ong, Lingzhi Wang, Boon-Cher Goh (2021) - Frontiers in pharmacology
  11. Targeting autophagy enhances the anticancer effect of artemisinin and its derivatives.
    Xin Sun, Peiyi Yan, Chang Zou, Yin-Kwan Wong, Yuhan Shu, Yew Mun Lee, Chongjing Zhang, Nai-Di Yang, Jigang Wang, Jianbin Zhang (2019) - Medicinal research reviews
  12. Advances in the research on the targets of anti-malaria actions of artemisinin.
    Jing Yang, Yingke He, Yinbao Li, Xing Zhang, Yin-Kwan Wong, Shengnan Shen, Tianyu Zhong, Jianbin Zhang, Qian Liu, Jigang Wang (2020) - Pharmacology & therapeutics
  13. Artemisinin-resistant malaria: research challenges, opportunities, and public health implications.
    Rick M Fairhurst, Gaurvika M L Nayyar, Joel G Breman, Rachel Hallett, Jonathan L Vennerstrom, Socheat Duong, Pascal Ringwald, Thomas E Wellems, Christopher V Plowe, Arjen M Dondorp (2012) - The American journal of tropical medicine and hygiene
  14. Antischistosomal activity of artemisinin derivatives in vivo and in patients.
    Mohamed E M Saeed, Sanjeev Krishna, Henry Johannes Greten, Peter G Kremsner, Thomas Efferth (2016) - Pharmacological research
  15. Current scenario of artemisinin and its analogues for antimalarial activity.
    Akriti Kumari, Manvika Karnatak, Davinder Singh, Ravi Shankar, Jawahar L Jat, Siddharth Sharma, Dinesh Yadav, Rahul Shrivastava, Ved Prakash Verma (2019) - European journal of medicinal chemistry
  16. TRICHOME AND ARTEMISININ REGULATOR 2 positively regulates trichome development and artemisinin biosynthesis in Artemisia annua.
    Zheng Zhou, Hexin Tan, Qi Li, Qing Li, Yun Wang, Qitao Bu, Yaoxin Li, Yu Wu, Wansheng Chen, Lei Zhang (2020) - The New phytologist
  17. Photoaffinity probe-based antimalarial target identification of artemisinin in the intraerythrocytic developmental cycle of
    Peng Gao, Jianyou Wang, Chong Qiu, Huimin Zhang, Chen Wang, Ying Zhang, Peng Sun, Honglin Chen, Yin Kwan Wong, Jiayun Chen, Junzhe Zhang, Huan Tang, Qiaoli Shi, Yongping Zhu, Shengnan Shen, Guang Han, Chengchao Xu, Lingyun Dai, Jigang Wang (2024) - iMeta
  18. Cancer combination therapies with artemisinin-type drugs.
    Thomas Efferth (2017) - Biochemical pharmacology
  19. Recent Advances in the Treatment of Malaria.
    Jawaher M Alghamdi, Arwa A Al-Qahtani, Fatimah S Alhamlan, Ahmed A Al-Qahtani (2024) - Pharmaceutics
  20. Research Advances on Health Effects of Edible
    Antoaneta Trendafilova, Laila M Moujir, Pedro M C Sousa, Ana M L Seca (2020) - Foods (Basel, Switzerland)


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!